A phase i, single-dose study to evaluate the safety, tolerability, and pharmacokinetics of asc43f, a fixed-dose combination oral tablet of asc41, a thyroid hormone receptor beta agonist and asc42, a farnesoid x receptor agonist in healthy subjects